Asset profile
Synthetic hypericin
Small molecule
Evidence outlook · registrational
Cutaneous T-Cell Lymphoma: registrational trials complete, results ungraded
Its supporting mid-stage evidence has not yet been graded on this platform. Its registrational studies have completed; results have not been graded on this platform. Check News and the registry record for topline outcomes.
Also in development:Psoriasis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 61 same-indication; 26 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Synthetic Hypericin: this drug | Phase 3 | Small molecule | Photosensitizer (visible-light activated) | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A | ||
| Calcipotriene / Betamethasone Dipropionate Cream (Wynzora) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Calcipotriene / Betamethasone Dipropionate Foam (Enstilar) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| Desoximetasone (Topicort Spray) | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Halobetasol Propionate Foam (Lexette) | Approved | Small molecule | Glucocorticoid receptor | ||
| Halobetasol Propionate Lotion (Bryhali) | Approved | Small molecule | Glucocorticoid receptor | ||
| Halobetasol Propionate / Tazarotene (Duobrii) | Approved | Small molecule | Glucocorticoid receptor + retinoic acid receptor |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.